Active Research
The Anatomy of Treatment Cost
Status: In Progress
A gene therapy can cure a child's blindness. It costs $850,000 per eye. This project dissects the cost structure of biological treatments — from R&D amortization to manufacturing complexity to pricing strategy — to identify where structural intervention could bring costs down without killing innovation.
Deliverables:
- Cost breakdown analysis of 10 landmark biological treatments
- Comparison of pricing models across US, EU, and emerging markets
- Policy brief on cost-reduction levers available to regulators
First research note published: "The Accessibility Crisis in Biological Medicine"
Pipeline Bottleneck Analysis
Status: Scoping
It takes 10–15 years and $2 billion to bring a drug from lab to patient. Where exactly is the bottleneck? This project maps the drug development pipeline stage by stage, measuring time and cost at each gate, to identify where compression is feasible.
Research questions:
- What fraction of total development time is regulatory vs. scientific vs. manufacturing?
- Which stages have seen the least efficiency improvement over the past 20 years?
- What can be learned from fields with faster development cycles (software, materials science)?
Orphan Drug Economics
Status: Early Research
Rare diseases collectively affect over 300 million people worldwide. But each individual condition is "too rare" to justify standard pharmaceutical investment. This project analyzes alternative economic models — subscription pricing, international risk pooling, AI-accelerated trial design — that could make rare disease treatment financially viable.
Precision Medicine at Scale
Status: Scoping
Precision medicine promises treatments tailored to your genome. But hospitals, insurers, and supply chains were built for standardized care. This project studies the systemic adaptations — in logistics, data infrastructure, reimbursement models, and clinical workflows — needed to deliver personalized medicine beyond research hospitals.